NAPSRx CNPR Exam Practice Questions with Verified
Answers | 100 Questions with Detailed Rationales
(2026/2027 Edition)
SECTION 1: Pharmacology & Pharmaceutical Sciences
Question 1
Which process describes the movement of a drug from its site of administration into the
bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug enters the bloodstream from its
site of administration. Distribution refers to drug movement throughout body tissues,
metabolism is chemical transformation, and excretion is elimination from the body.
Question 2
A pharmaceutical representative is discussing bioequivalence with a pharmacist.
According to FDA standards, two drug products are considered bioequivalent if they
have:
A. Identical inactive ingredients
B. The same color and shape
C. Equivalent rates and extents of absorption
D. Identical manufacturing processes
Correct Answer: C
Rationale: Bioequivalence is determined by the rate and extent of active ingredient
absorption, not by inactive ingredients, appearance, or manufacturing processes. This is
the standard used for generic drug approval.
Question 3
,The pharmacological term "therapeutic index" refers to:
A. The ratio between the toxic dose and the effective dose
B. The number of patients who respond to treatment
C. The time required to reach peak plasma concentration
D. The percentage of drug bound to plasma proteins
Correct Answer: A
Rationale: The therapeutic index is the ratio of the toxic dose to the effective dose
(TD50/ED50), indicating the safety margin of a drug. A narrow therapeutic index means
toxicity occurs close to effective doses.
Question 4
Which DEA schedule classification indicates substances with no currently accepted
medical use and a high potential for abuse?
A. Schedule II
B. Schedule III
C. Schedule IV
D. Schedule I
Correct Answer: D
Rationale: Schedule I substances have no accepted medical use and high abuse
potential. Schedules II-V have accepted medical uses with decreasing abuse potential.
Question 5
First-pass metabolism primarily occurs in which organ?
A. Kidneys
B. Liver
C. Lungs
D. Small intestine
Correct Answer: B
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract travel
via the portal vein to the liver before entering systemic circulation, where hepatic
enzymes may metabolize a significant portion.
Question 6
,A drug with high plasma protein binding will:
A. Cross the blood-brain barrier more easily
B. Have a longer duration of action
C. Be eliminated more rapidly by the kidneys
D. Show increased free drug concentration at receptor sites
Correct Answer: B
Rationale: Protein-bound drug acts as a reservoir, releasing free drug slowly. This
typically prolongs duration of action. Bound drug cannot cross membranes easily, be
filtered by kidneys, or interact with receptors.
Question 7
The primary difference between pharmacokinetics and pharmacodynamics is that
pharmacokinetics describes:
A. What the drug does to the body, while pharmacodynamics describes what the body
does to the drug
B. What the body does to the drug, while pharmacodynamics describes what the drug
does to the body
C. Drug interactions, while pharmacodynamics describes side effects
D. Drug absorption, while pharmacodynamics describes drug distribution
Correct Answer: B
Rationale: Pharmacokinetics (ADME) describes what the body does to the drug.
Pharmacodynamics describes the biochemical and physiological effects of the drug on
the body.
Question 8
Which route of administration provides the most rapid onset of action?
A. Oral
B. Subcutaneous
C. Intravenous
D. Transdermal
Correct Answer: C
, Rationale: Intravenous administration delivers drug directly into the bloodstream,
bypassing absorption barriers and providing immediate systemic availability. Oral,
subcutaneous, and transdermal routes require absorption time.
Question 9
An antagonist drug works by:
A. Binding to a receptor and producing the same effect as the endogenous substance
B. Binding to a receptor and blocking the action of other substances
C. Increasing the synthesis of neurotransmitters
D. Enhancing the metabolism of other drugs
Correct Answer: B
Rationale: An antagonist binds to receptors without activating them, thereby blocking
agonists or endogenous substances from producing their effects. Agonists produce
receptor activation.
Question 10
Which of the following is an example of a drug-drug interaction involving enzyme
inhibition?
A. Warfarin and aspirin increasing bleeding risk
B. Erythromycin increasing the plasma levels of simvastatin
C. Penicillin and probenecid competing for renal tubular secretion
D. Aluminum antacids reducing levothyroxine absorption
Correct Answer: B
Rationale: Erythromycin inhibits CYP3A4 enzymes, reducing simvastatin metabolism
and increasing its plasma levels. This is a metabolic enzyme inhibition interaction.
Question 11
The Orange Book published by the FDA is primarily used to identify:
A. Approved drug products with therapeutic equivalence evaluations
B. Drugs that have been recalled from the market
C. Investigational drugs currently in clinical trials
D. Controlled substance scheduling classifications
Correct Answer: A
Answers | 100 Questions with Detailed Rationales
(2026/2027 Edition)
SECTION 1: Pharmacology & Pharmaceutical Sciences
Question 1
Which process describes the movement of a drug from its site of administration into the
bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug enters the bloodstream from its
site of administration. Distribution refers to drug movement throughout body tissues,
metabolism is chemical transformation, and excretion is elimination from the body.
Question 2
A pharmaceutical representative is discussing bioequivalence with a pharmacist.
According to FDA standards, two drug products are considered bioequivalent if they
have:
A. Identical inactive ingredients
B. The same color and shape
C. Equivalent rates and extents of absorption
D. Identical manufacturing processes
Correct Answer: C
Rationale: Bioequivalence is determined by the rate and extent of active ingredient
absorption, not by inactive ingredients, appearance, or manufacturing processes. This is
the standard used for generic drug approval.
Question 3
,The pharmacological term "therapeutic index" refers to:
A. The ratio between the toxic dose and the effective dose
B. The number of patients who respond to treatment
C. The time required to reach peak plasma concentration
D. The percentage of drug bound to plasma proteins
Correct Answer: A
Rationale: The therapeutic index is the ratio of the toxic dose to the effective dose
(TD50/ED50), indicating the safety margin of a drug. A narrow therapeutic index means
toxicity occurs close to effective doses.
Question 4
Which DEA schedule classification indicates substances with no currently accepted
medical use and a high potential for abuse?
A. Schedule II
B. Schedule III
C. Schedule IV
D. Schedule I
Correct Answer: D
Rationale: Schedule I substances have no accepted medical use and high abuse
potential. Schedules II-V have accepted medical uses with decreasing abuse potential.
Question 5
First-pass metabolism primarily occurs in which organ?
A. Kidneys
B. Liver
C. Lungs
D. Small intestine
Correct Answer: B
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract travel
via the portal vein to the liver before entering systemic circulation, where hepatic
enzymes may metabolize a significant portion.
Question 6
,A drug with high plasma protein binding will:
A. Cross the blood-brain barrier more easily
B. Have a longer duration of action
C. Be eliminated more rapidly by the kidneys
D. Show increased free drug concentration at receptor sites
Correct Answer: B
Rationale: Protein-bound drug acts as a reservoir, releasing free drug slowly. This
typically prolongs duration of action. Bound drug cannot cross membranes easily, be
filtered by kidneys, or interact with receptors.
Question 7
The primary difference between pharmacokinetics and pharmacodynamics is that
pharmacokinetics describes:
A. What the drug does to the body, while pharmacodynamics describes what the body
does to the drug
B. What the body does to the drug, while pharmacodynamics describes what the drug
does to the body
C. Drug interactions, while pharmacodynamics describes side effects
D. Drug absorption, while pharmacodynamics describes drug distribution
Correct Answer: B
Rationale: Pharmacokinetics (ADME) describes what the body does to the drug.
Pharmacodynamics describes the biochemical and physiological effects of the drug on
the body.
Question 8
Which route of administration provides the most rapid onset of action?
A. Oral
B. Subcutaneous
C. Intravenous
D. Transdermal
Correct Answer: C
, Rationale: Intravenous administration delivers drug directly into the bloodstream,
bypassing absorption barriers and providing immediate systemic availability. Oral,
subcutaneous, and transdermal routes require absorption time.
Question 9
An antagonist drug works by:
A. Binding to a receptor and producing the same effect as the endogenous substance
B. Binding to a receptor and blocking the action of other substances
C. Increasing the synthesis of neurotransmitters
D. Enhancing the metabolism of other drugs
Correct Answer: B
Rationale: An antagonist binds to receptors without activating them, thereby blocking
agonists or endogenous substances from producing their effects. Agonists produce
receptor activation.
Question 10
Which of the following is an example of a drug-drug interaction involving enzyme
inhibition?
A. Warfarin and aspirin increasing bleeding risk
B. Erythromycin increasing the plasma levels of simvastatin
C. Penicillin and probenecid competing for renal tubular secretion
D. Aluminum antacids reducing levothyroxine absorption
Correct Answer: B
Rationale: Erythromycin inhibits CYP3A4 enzymes, reducing simvastatin metabolism
and increasing its plasma levels. This is a metabolic enzyme inhibition interaction.
Question 11
The Orange Book published by the FDA is primarily used to identify:
A. Approved drug products with therapeutic equivalence evaluations
B. Drugs that have been recalled from the market
C. Investigational drugs currently in clinical trials
D. Controlled substance scheduling classifications
Correct Answer: A
